중증천식의 생물학적 제제 치료

키워드

참고문헌 (57)

1. Beasley R, "The burden of asthma with specific reference to the United States", J Allergy Clin Immunol, 109(5 Suppl), pp.S482~S489 (2002)[DOI]
2. 조상헌, "The Current Status of Asthma in Korea", Journal of Korean Medical Science, 21(2), pp.181~187 (2006), 대한의학회
3. Kim SH, "Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals", J Asthma, 49, pp.303~309 (2012)[DOI]
4. Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
5. Katial RK, "Changing paradigms in the treatment of severe asthma: the role of biologic therapies", J Allergy Clin Immunol Pract, 5(2S), pp.S1~S14 (2017)[DOI]
6. "Global Strategy for Asthma Management and Prevention" (2017)[URL]
7. Newby C, "Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability", PloS one, 9, pp.e102987~ (2014)[DOI]
8. Wenzel SE, "Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics", Am J Respir Crit Care Med, 160, pp.1001~1008 (1999)[DOI]
9. Schleich F, "Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)", Respir Med, 108, pp.1723~1732 (2014)[DOI]
10. Diver S, "New and emerging drug treatments for severe asthma", Clin Exp Allergy, 48, pp.241~252 (2018)[DOI]
11. Chang HS, "Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations", Expert Rev Respir Med, 11, pp.29~40 (2017)[DOI]
12. Strunk RC, "Omalizumab for asthma", N Engl J Med, 354, pp.2689~2695 (2006)[DOI]
13. Busse W, "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma", J Allergy Clin Immunol, 108, pp.184~190 (2001)[DOI]
14. Soler M, "The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics", Eur Respir J, 18, pp.254~261 (2001)[DOI]
15. Hanania NA, "Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial", Ann Intern Med, 154, pp.573~582 (2011)[DOI]
16. Rodrigo GJ, "Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review", Chest, 139, pp.28~35 (2011)[DOI]
17. Normansell R, "Omalizumab for asthma in adults and children", Cochrane Database Syst Rev, (1) (2014)
18. Bousquet J, "Predicting and evaluating response to omalizumab in patients with severe allergic asthma", Respir Med, 101, pp.1483~1492 (2007)[DOI]
19. Wahn U, "Relationship between pretreatment specific IgE and the response to omalizumab therapy", Allergy, 64, pp.1780~1787 (2009)[DOI]
20. Hanania NA, "Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study", Am J Respir Crit Care Med, 187, pp.804~811 (2013)[DOI]
21. Humbert M, "Omalizumab in asthma: an update on recent developments", J Allergy Clin Immunol Pract, 2, pp.525~536 (2014)[DOI]
22. Busse W, "Omalizumab and the risk of malignancy: results from a pooled analysis", J Allergy Clin Immunol, 129, pp.983~989 (2012)[DOI]
23. Long A, "Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab", J Allergy Clin Immunol, 134, pp.560~567 (2014)[DOI]
24. Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma", N Engl J Med, 360, pp.973~984 (2009)[DOI]
25. Pavord ID, "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)[DOI]
26. Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma", N Engl J Med, 371, pp.1198~1207 (2014)[DOI]
27. Yancey SW, "Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma", J Allergy Clin Immunol, 139, pp.1167~1175 (2017)[DOI]
28. Nair P, "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia", N Engl J Med, 360, pp.985~993 (2009)[DOI]
29. Bel EH, "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma", N Engl J Med, 371, pp.1189~1197 (2014)[DOI]
30. Chupp GL, "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial", Lancet Respir Med, 5, pp.390~400 (2017)[DOI]
31. Haldar P, "Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis", J Allergy Clin Immunol, 133, pp.921~923 (2014)[DOI]
32. Castro M, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials", Lancet Respir Med, 3, pp.355~366 (2015)[DOI]
33. Brusselle G, "Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy", ERJ Open Res, 3, pp.00004~2017 (2017)
34. Mukherjee M, "Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab", Am J Respir Crit Care Med, 197, pp.38~46 (2018)[DOI]
35. Busse WW, "Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma", J Allergy Clin Immunol, 125, pp.1237~1244 (2010)[DOI]
36. Castro M, "Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study", Lancet Respir Med, 2, pp.879~890 (2014)[DOI]
37. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)[DOI]
38. Bleecker ER, "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting <TEX>${\beta}2$<", TEX>-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, 2016, pp.388, 2115~2127
39. FitzGerald JM, "Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies", Lancet Respir Med, 6, pp.51~64 (2018)[DOI]
40. Nair P, "Oral glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)[DOI]
41. Wenzel S, "Dupilumab in persistent asthma with elevated eosinophil levels", N Engl J Med, 368, pp.2455~2466 (2013)[DOI]
42. Wenzel S, "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting <TEX>${\beta}$<", TEX>-2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial, 2016, pp.388, 31~44
43. Dunn RM, "Anti-interleukin therapy in asthma", Clin Pharmacol Ther, 97, pp.55~65 (2015)[DOI]
44. Bachert C, "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial", JAMA, 315, pp.469~479 (2016)[DOI]
45. Blauvelt A, "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial", Lancet, 389, pp.2287~2303 (2017)[DOI]
46. Hanania NA, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials", Lancet Respir Med, 4, pp.781~796 (2016)[DOI]
47. Brightling CE, "Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial", Lancet Respir Med, 3, pp.692~701 (2015)[DOI]
48. Fajt ML, "Prostaglandin <TEX>$D_2$<", TEX> pathway upregulation: relation to asthma severity, control, and TH2 inflammation, 2013, pp.131, 1504~1512
49. Gonem S, "Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial", Lancet Respir Med, 4, pp.699~707 (2016)[DOI]
50. Shikotra A, "Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma", J Allergy Clin Immunol, 129, pp.104~111 (2012)[DOI]
51. Gauvreau GM, "Effects of an anti-TSLP antibody on allergen-induced asthmatic responses", N Engl J Med, 370, pp.2102~2110 (2014)[DOI]
52. Corren J, "Tezepelumab in adults with uncontrolled asthma", N Engl J Med, 377, pp.936~946 (2017)[DOI]
53. Wenzel SE, "A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma", Am J Respir Crit Care Med, 179, pp.549~558 (2009)[DOI]
54. Morjaria JB, "The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial", Thorax, 63, pp.584~591 (2008)[DOI]
55. Holgate ST, "Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial", Eur Respir J, 37, pp.1352~1359 (2011)[DOI]
56. O'Byrne PM, "Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebocontrolled trial", Lancet Respir Med, 4, pp.797~806 (2016)[DOI]
57. Busse WW, "Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma", Am J Respir Crit Care Med, 188, pp.1294~1302 (2013)[DOI]

관련 논문AI추천